QTTB Q32 Bio Corp: רווח נקי למניה ב-12 החודשים האחרונים

Geopolitical tensions and sanctions are hindering the clinical trials of Q32 Bio Inc. (QTTB), which corroborates the historical YoY EPS growth over the last 12 months, where 197.20 reflects the latest level of the metric. Q32 Bio Inc. (QTTB) relies on patent protection for antibodies treating autoimmune pathologies, which ensures high margins. Meanwhile, management is maintaining a sufficient cash reserve to fund advanced stages of research.

Fundamental asset selection is based on an analysis of profit dynamics, where a steady acceleration in returns confirms the resilience of the business model. This indicator measures the rolling annual growth rate of net income per share, reflecting the R&D capital efficiency derived from Big Pharma alliances and the regulatory success of Q32 Bio Inc. (QTTB), which clearly demonstrates the current YoY ttm growth in net income per share.